Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MNKD logo MNKD
Upturn stock ratingUpturn stock rating
MNKD logo

MannKind Corp (MNKD)

Upturn stock ratingUpturn stock rating
$3.76
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: MNKD (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

7 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $9.71

Year Target Price $9.71

Analyst’s Price TargetsFor last 52 week
$9.71Target price
Low$3.63
Current$3.76
high$7.63

Analysis of Past Performance

Type Stock
Historic Profit 26.59%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.14B USD
Price to earnings Ratio 37.6
1Y Target Price 9.43
Price to earnings Ratio 37.6
1Y Target Price 9.43
Volume (30-day avg) -
Beta 1.01
52 Weeks Range 3.63 - 7.63
Updated Date 06/29/2025
52 Weeks Range 3.63 - 7.63
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.1

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 10.12%
Operating Margin (TTM) 31.65%

Management Effectiveness

Return on Assets (TTM) 10.97%
Return on Equity (TTM) -

Valuation

Trailing PE 37.6
Forward PE 25.06
Enterprise Value 1006976859
Price to Sales(TTM) 3.84
Enterprise Value 1006976859
Price to Sales(TTM) 3.84
Enterprise Value to Revenue 3.38
Enterprise Value to EBITDA 12.19
Shares Outstanding 303932992
Shares Floating 298155088
Shares Outstanding 303932992
Shares Floating 298155088
Percent Insiders 1.86
Percent Institutions 58.64

Analyst Ratings

Rating 4.86
Target Price 9.71
Buy 1
Strong Buy 6
Buy 1
Strong Buy 6
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

MannKind Corp

stock logo

Company Overview

overview logo History and Background

MannKind Corp. was founded in 1991. It is a biopharmaceutical company focused on the discovery, development, and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases.

business area logo Core Business Areas

  • Pulmonary Therapies: Focuses on developing and commercializing therapies for pulmonary diseases.
  • Endocrine Therapies: Focuses on therapies addressing endocrine disorders.
  • Technosphere Technology: MannKind's proprietary drug formulation platform.

leadership logo Leadership and Structure

Michael Castagna is the Chief Executive Officer. The company has a typical organizational structure with departments focused on research and development, commercial operations, finance, and administration.

Top Products and Market Share

overview logo Key Offerings

  • Afrezza: An inhaled insulin product for adults with diabetes mellitus. While precise market share data is difficult to obtain, it competes with injectable insulins from Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY). Afrezza is differentiated by its rapid onset and short duration of action. Revenue in 2023 was roughly $60 million. Afrezza competitors include Lantus (Sanofi), Humalog (Eli Lilly), and Novolog (Novo Nordisk)
  • Tyvaso DPI: An inhaled dry powder formulation of treprostinil developed in collaboration with United Therapeutics (UTHR) for the treatment of pulmonary hypertension. Tyvaso DPI's competitors include other prostacyclin analogues and PDE5 inhibitors.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and strong competition. The inhaled drug delivery market is growing due to its convenience and effectiveness.

Positioning

MannKind is a niche player focusing on inhaled drug delivery. Its competitive advantage lies in its Technosphere platform, which allows for rapid drug absorption.

Total Addressable Market (TAM)

The estimated TAM for inhaled insulin and pulmonary hypertension therapies is several billion dollars. MannKind is positioned to capture a portion of this TAM through Afrezza and Tyvaso DPI.

Upturn SWOT Analysis

Strengths

  • Proprietary Technosphere technology
  • Partnership with United Therapeutics
  • Rapid onset of action of Afrezza

Weaknesses

  • Limited financial resources
  • Dependence on a few key products
  • History of losses

Opportunities

  • Expansion of Afrezza into new markets
  • Development of new products using Technosphere technology
  • Potential for acquisitions or partnerships

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent expiration

Competitors and Market Share

competitor logo Key Competitors

  • NVO
  • LLY
  • SNY
  • UTHR

Competitive Landscape

MannKind competes with larger pharmaceutical companies. Its Technosphere platform offers a competitive advantage, but its financial resources are limited.

Growth Trajectory and Initiatives

Historical Growth: MannKind has experienced fluctuating revenue growth. Recent partnerships and product approvals suggest potential for future growth.

Future Projections: Analyst estimates vary, but generally project revenue growth driven by Afrezza and Tyvaso DPI sales.

Recent Initiatives: Commercial partnerships like with United Therapeutics for Tyvaso DPI, ongoing clinical trials and regulatory submissions.

Summary

MannKind Corp is a biopharmaceutical company with innovative inhaled drug delivery technology. Its strengths lie in its Technosphere platform and partnerships, but it faces challenges due to its limited resources and competition. Recent initiatives and growth in Tyvaso DPI sales show promise. The company needs to carefully manage its finances and expand its product pipeline to achieve sustainable growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC filings (10-K, 10-Q)
  • Company press releases
  • Analyst reports
  • Company Website

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and may vary. Investing in pharmaceutical companies involves risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MannKind Corp

Exchange NASDAQ
Headquaters Danbury, CT, United States
IPO Launch date 2004-07-28
CEO & Director Dr. Michael E. Castagna Pharm.D.
Sector Healthcare
Industry Biotechnology
Full time employees 403
Full time employees 403

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.